Over the last decade, there have been numerous developments and changes in treatment
practices for the management of patients with immune thrombocytopenia (ITP). This article is …

Key Clinical Points Immune Thrombocytopenia Immune thrombocytopenia (ITP) is
diagnosed in patients with a platelet count below 100,000 per cubic millimeter in whom …

Summary Each year, the American Heart Association (AHA), in conjunction with the Centers
for Disease Control and Prevention, the National Institutes of Health, and other government …

Summary Each year, the American Heart Association (AHA), in conjunction with the Centers
for Disease Control and Prevention, the National Institutes of Health, and other government …

Abstract In phase 2/3 trials, eltrombopag treatment of 6 months or less in patients with
chronic/persistent immune thrombocytopenia (ITP) increased platelet counts and reduced …

Primary immune thrombocytopenia (ITP) is an immune-mediated bleeding disorder
characterized by decreased platelet counts and an increased risk of bleeding. Multiple …

Thrombosis can affect any venous circulation. Venous thromboembolism (VTE) includes
deep-vein thrombosis of the leg or pelvis, and its complication, pulmonary embolism. VTE is …

Venous thromboembolism (VTE) is categorized by the US Surgeon General as a major
public health problem. VTE is relatively common and associated with reduced survival and …

Asplenia (the congenital or acquired absence of the spleen) and hyposplenism (defective
spleen function) are common causes of morbidity and mortality. The spleen is a secondary …

Immune thrombocytopenia (ITP) is the most common acquired thrombocytopenia after
chemotherapy-induced thrombocytopenia. Existing guidelines describe the management …